awmsg logo



brexpiprazole (Rexulti®)


Reference No. 1372

Publication date:
20/12/2018


Appraisal information

brexpiprazole (Rexulti®) 0.25 mg film-coated tablet
brexpiprazole (Rexulti®) 0.5 mg film-coated tablet
brexpiprazole (Rexulti®) 1 mg film-coated tablet
brexpiprazole (Rexulti®) 2 mg film-coated tablet
brexpiprazole (Rexulti®) 3 mg film-coated tablet
brexpiprazole (Rexulti®) 4 mg film-coated tablet


Company: Otsuka Pharmaceutical (UK) Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 19/12/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, Brexpiprazole (Rexulti®) cannot be endorsed for use within NHS Wales for the treatment of schizophrenia in adult patients.
Statement of Advice (SOA)
Download